AbbVie has acquired Apogee Therapeutics in a deal worth $10.9 billion, according to Endpoints News. The purchase, completed last month, caps a long courtship between the Chicago-area pharmaceutical giant and the biotech firm.
According to Endpoints News, the two companies had been in discussions for years before reaching an agreement. The report frames the transaction as the culmination of a drawn-out relationship rather than a sudden move, with AbbVie holding talks with Apogee over an extended period before the deal came together.
Endpoints News published the details as part of a broader roundup that also touched on the UK launching a drug pricing pilot and news involving Brii Biosciences.
The specific terms beyond the $10.9 billion price, and the drugs or pipeline assets that drew AbbVie to Apogee, were not detailed in the source material available here.
Why it matters: Multibillion-dollar acquisitions like this are how large drugmakers such as AbbVie replenish their pipelines, and a $10.9 billion price tag signals how much value the company sees in Apogee's programs — a bet that can shape which new treatments eventually reach patients.